Formulation and Evaluation of Combinational Capsule of Metoprolol Succinate and Atorvastatin Calcium

Hypertensive patients commonly exhibit lipid abnormalities and frequently require statins in combination with the antihypertensive therapy. So, an attempt has been made to formulate the Metoprolol succinate extended release and Atorvastatin calcium combinational capsules. Metoprolol succinate is the cardio-selective β-adrenoreceptor blocking agent used to treat hypertension. Atorvastatin is a synthetic lipid lowering agent and it is an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A(HMG-COA) reductase. To match the release pattern of the Atorvastatin calcium with the theoretical release profiles different formulation trials were under taken. Among all the six formulations, the release profile of trial F-6 was found to be similar to the theoretical release profiles. The capsules were evaluated for uniformity of weight, locking length, assay, water content and content uniformity.